Therapy for Whipple's disease.
Whipple's disease was first described in 1907, the genomic composition of the causative organism, Tropheryma whipplei, was unravelled in 2003 and its in vitro susceptibility to antibiotics started to be explored in 2004-05. Still today, this knowledge is not fully applied in the recommendations for the therapy of this disease. In this paper, we summarize the current recommendations on antimicrobial therapy for Whipple's disease and propose a shift in the maintenance therapy.
Knaapen
Hanneke K A
HK
Department of Rheumatology, University Medical Centre Nijmegen St Radboud, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Barrera
Pilar
P
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D006801:Humans; D009422:Nervous System Diseases / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use; D008061:Whipple Disease / Q000150:complications / Q000188:drug therapy* / Q000473:pathology
D000900:Anti-Bacterial Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination